Gastrointestinal Cancer | Specialty

Early Efficacy Data With RP2 in Advanced Solid Tumors

November 13th 2020

Francesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.

Urelumab Induces Additive Benefit With Vaccine/Nivolumab Combo in Pancreatic Cancer

November 13th 2020

November 13, 2020 – The addition of urelumab, an anti-CD137 agonist to the GVAX vaccine and nivolumab led to a 30% pathologic response rate and was associated with mild toxicity as neoadjuvant or adjuvant therapy in patients with resectable pancreatic ductal adenocarcinoma.

CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC

November 13th 2020

November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.

Bemarituzumab Plus Chemotherapy Significantly Improves Survival in FGFRb+ Gastric/GEJ Cancer

November 11th 2020

The addition of the first-in-class targeted therapy bemarituzumab to chemotherapy significantly improved progression-free survival and overall survival versus chemotherapy alone in the frontline treatment of patients with FGFRb-positive, locally advanced or metastatic gastric and gastroesophageal junction cancer.

Dr. Zalcberg on the Role of Ripretinib in Advanced GIST

November 10th 2020

John Zalcberg, ​PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor​.

Dr. Benson on the Complexity of Up-front Treatment in HCC

November 10th 2020

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

Unlocking the Potential of Targeted Treatment Options for HCC

November 6th 2020

Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.

Dr. Sun on the Use of Ramucirumab/Paclitaxel in Metastatic Gastric Cancer

November 5th 2020

Weijing Sun, MD, FACP, discusses the ​use of ramucirumab plus paclitaxel in metastatic gastric cancer.

Atezolizumab/Bevacizumab Approved in Europe for Advanced or Unresectable HCC

November 2nd 2020

The European Commission has approved the combination of atezolizumab plus bevacizumab for use in adult patients with advanced or unresectable hepatocellular carcinoma who have not been given previous systemic therapy.

Selective Dismutase Mimetic/SBRT Improves OS in Locally Advanced Pancreatic Cancer

November 2nd 2020

The addition of avasopasem manganese to stereotactic body radiation therapy led to a significant improvement in overall survival and favorable progression-free survival versus SBRT plus placebo in patients with locally advanced pancreatic cancer.

Atezolizumab Plus Bevacizumab Approved in China for Hepatocellular Carcinoma

October 30th 2020

The China National Medical Products Administration has approved the combination of atezolizumab plus bevacizumab for use in patients with unresectable hepatocellular carcinoma who have not received previous systemic therapy.

Dr. Wolin on the Treatment Landscape of NETs

October 29th 2020

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

Dr. Goff on the Need to Identify Novel Targets in HCC

October 29th 2020

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer

October 29th 2020

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Gastric Cancer

October 28th 2020

The FDA has accepted and granted a priority review designation to a supplemental biologics license application for the antibody-drug conjugate trastuzumab deruxtecan for use in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma.

New Predictive Test Gains Momentum With 2 Positive Studies in Localized Colon Cancer

October 26th 2020

Immunoscore®, a host immune response classification tool, has demonstrated the ability to significantly affect treatment decision-making for patients with stage II colon cancer, particularly among those with high-risk disease.

Applying Data to the Real World in Gastric Cancer

October 22nd 2020

Emerging Approaches in HER2+ Gastric Cancers

October 22nd 2020

VEGFR TKIs in Gastroesophageal Cancer

October 22nd 2020

Maintenance Therapy in Gastric Cancers

October 22nd 2020